Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2006

Caprion Enters Oncology Target Licensing Agreement with Centocor

  • Caprion Pharmaceuticals will contribute protein targets to Centocor Research and Development for the development of Mabs and other therapeutic products for various cancer indications under a recent license agreement between the two companies.

    Caprion will select promising cancer targets using its CellCarta® proteomics technology platform. Centocor will have exclusive, worldwide rights to develop and commercialize therapeutics against any target it selects.

    The financial terms of the agreement include an upfront payment, license fees, milestone payments relating to the development of products by Centocor, and royalties on commercial sales of such products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »